Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

We recently published a list of Top 10 Best Dividend Stocks on Robinhood. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best dividend stocks ...

Merck must face trial on a Black IT director’s claims that racial bias drove his firing after he ordered the removal of a ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $98.28 which represents a slight increase of $0.83 or 0.85% from the prior close of $97.45. The stock opened at $97.42 and touched a ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, recommended ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...